ArticleDigestive diseases and sciences2026

Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease.

Andrew R Roney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.